Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY -6.00%67 Forward Rate of Return (Yacktman) % is 17.01% as of Jun. 2026, which is 3% below its 10-year median of 17.60. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 636 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 75.63% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Swedish Orphan Biovitrum AB's forward rate of return for was 17.01%.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % or its related term are showing as below:
SWOBY'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.74 Med: 17.6 Max: 21.38
Current: 17.03
During the past 13 years, Swedish Orphan Biovitrum AB's highest Forward Rate of Return was 21.38. The lowest was 5.74. And the median was 17.60.
SWOBY's Forward Rate of Return (Yacktman) % is ranked better than 75.63% of 636
companies
in the Drug Manufacturers industry
Industry Median: 6.6
vs SWOBY: 17.03
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Swedish Orphan Biovitrum AB Forward Rate of Return (Yacktman) % Related Terms
Swedish Orphan Biovitrum AB Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Forward Rate of Return (Yacktman) % Chart
SWOBY vs ZTS: Forward Rate of Return (Yacktman) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Forward Rate of Return (Yacktman) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % falls into.
Swedish Orphan Biovitrum AB Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 17.01% mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Forward Rate of Return (Yacktman) % of 17.01% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 17.60. Over the past decade, Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % has ranged from 5.74 to 21.38. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #155 out of 636 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % too high?
Swedish Orphan Biovitrum AB's current Forward Rate of Return (Yacktman) % of 17.01% is near median its 10-year median of 17.60. Over the past 10 years, this metric has ranged from a low of 5.74 to a high of 21.38. The Drug Manufacturers industry median Forward Rate of Return (Yacktman) % is 6.60. Swedish Orphan Biovitrum AB's value of 17.01% is 157.7% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #155 out of 636 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #155 out of 636 companies for Forward Rate of Return (Yacktman) %. This places Swedish Orphan Biovitrum AB in the top 24% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 6.60. Swedish Orphan Biovitrum AB's value of 17.01% is 157.7% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Forward Rate of Return (Yacktman) % has ranged from 5.74 to 21.38 over the past decade. While the company's 10-year median is 17.60 vs. the industry median of 6.60, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Drug Manufacturers company?
The median Forward Rate of Return (Yacktman) % among Drug Manufacturers companies is 6.60, based on 636 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Forward Rate of Return (Yacktman) % of 17.01% is 157.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Forward Rate of Return (Yacktman) % is 6.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Forward Rate of Return (Yacktman) % is 17.01%, which is near median its own 10-year median of 17.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 17.01%, which is near median its 10-year median of 17.60 and 157.7% above the Drug Manufacturers industry median of 6.60. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Forward Rate of Return (Yacktman) % is 17.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
Forward Rate of Return (Yacktman) %: 17.01% (near median its 10-year median of 17.60)
GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
Industry Position: 157.7% above the Drug Manufacturers median (#155 of 636)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
